Is Naltrexone Safe for the Liver? A Clear, Evidence-Based Answer

At the standard 50 mg therapeutic dose, naltrexone is safe for most people's livers. The FDA removed its liver-related black-box warning back in 2013.

What You'll Discover:

• Where the liver-safety concern originally came from and why it was overstated

• The critical difference between 50 mg (therapeutic dose) and 300 mg (the dose that caused problems)

• Who genuinely should not take naltrexone for liver reasons

• Why the liver damage from continued heavy drinking far outweighs any theoretical risk from the medication

• What liver monitoring looks like in practice when you start treatment

If you have heard that naltrexone can hurt your liver, you are not alone. That concern has a real origin and it has kept a lot of people from a medication that could genuinely help them. The short answer is that the science moved on quite a while ago, but the worry has not always kept pace.

What the Liver Safety Concern Is Really About

For years, naltrexone carried a black-box warning from the FDA flagging its potential to cause hepatocellular injury. A black-box warning is the most serious safety label the FDA places on a medication, so it is understandable that both patients and prescribers took it seriously.

The problem is that the warning was based on data from doses far higher than what is actually used to treat alcohol use disorder. The hepatotoxicity signal researchers observed was tied to doses of 300 mg per day or more, roughly six times the standard therapeutic dose of 50 mg. At those extreme doses, liver enzyme elevations were documented. At 50 mg, they largely were not.

The 2013 Black-Box Warning Removal

In 2013, after reviewing the accumulated evidence, the FDA removed the black-box liver warning from naltrexone. That decision reflected decades of clinical data showing that the standard 50 mg oral dose does not pose a meaningful hepatotoxic risk for patients with otherwise healthy liver function. The FDA retained a cautionary note advising against use in patients with severe hepatic impairment or acute hepatitis, but the most serious-level warning was gone.

Despite that regulatory update, the older concern has lingered in clinical practice. Many prescribers trained before 2013 still carry the original caution in their mental model of the drug. This is one reason naltrexone remains dramatically underprescribed relative to its evidence base, a topic covered in our article on why doctors are hesitant to prescribe naltrexone. The science has moved faster than the cultural norms in many prescribing settings.

The 300 mg vs. 50 mg Distinction That Changes Everything

This is the single most important clarification in the liver-safety conversation around naltrexone.

Research published in NCBI's clinical treatment guidelines confirms that hepatotoxic effects from naltrexone are dose-dependent and associated with doses of 300 mg per day or more. The standard oral dose for alcohol use disorder is 50 mg daily. That means the dose where liver problems were observed is six times higher than the dose used in treatment.

The same clinical reference explicitly states that naltrexone does not appear to be a hepatotoxin at the recommended doses. The rare hepatocellular injury cases in the literature involved either extremely high-dose use or confounding factors that were not fully controlled. In the context of treating alcohol use disorder, hepatotoxicity from naltrexone at 50 mg is not a clinically meaningful concern for patients without pre-existing severe liver disease.

For context on where the 300 mg figure comes from: early trials exploring naltrexone as a potential obesity treatment used much higher doses than what was later adopted for addiction medicine. Those high-dose obesity trials are where the liver signal emerged. The standard 50 mg dose for AUD was established separately, and the safety profile at that dose is far more favorable.

Who Should Not Take Naltrexone for Liver Reasons

While the evidence is reassuring for most patients, there are genuine contraindications related to liver health that any prescriber will screen for before writing a prescription.

Absolute Contraindications

Naltrexone is not appropriate for people who currently have:

• Acute hepatitis (active liver inflammation)

• Severe hepatic failure (end-stage liver disease)

• Current opioid use (a separate, non-liver contraindication)

These are hard stops. Someone in active hepatic crisis should not start naltrexone, and a responsible clinician will screen for this before prescribing.

The Gray Zone: Elevated Enzymes from Drinking

Here is where things get more nuanced, and more relevant, for many people researching this topic. Heavy drinking routinely elevates liver enzymes. If you have been drinking heavily and go get blood work, there is a good chance your ALT or AST numbers are above normal. That is not the same thing as severe hepatic failure or acute hepatitis.

Most clinicians use a practical threshold: liver function tests elevated 3 to 5 times above the normal upper limit are generally considered manageable, and naltrexone can often still be considered with appropriate monitoring. Tests elevated beyond that range call for more caution and individualized clinical judgment.

This matters because the alternative (continuing heavy drinking) is not neutral for your liver. It is actively destructive. A prescriber who dismisses naltrexone entirely because of a modest enzyme elevation, without weighing that against the ongoing damage from alcohol use, may not be giving you the full clinical picture.

Our guide to alcohol liver problem symptoms covers what those enzyme elevations mean and what the progression of alcohol-related liver damage actually looks like.

What Alcohol Is Already Doing to Your Liver

This context is essential and often left out of the conversation about naltrexone and liver safety.

Alcohol is a direct hepatotoxin. Chronic heavy drinking causes a well-documented progression of liver damage: fatty liver (which can develop within just a few weeks of heavy use), alcoholic hepatitis (active inflammation), and ultimately cirrhosis (irreversible scarring). According to the National Institute on Alcohol Abuse and Alcoholism, alcohol-related liver disease is one of the most preventable causes of chronic liver failure in the United States, driven entirely by ongoing alcohol consumption.

Heavy drinking also impairs the liver's ability to metabolize medications and toxins generally. The liver enzymes that prescribers check before starting naltrexone are, in most cases, elevated because of alcohol, not because of anything the naltrexone might do.

So when someone with alcohol use disorder asks whether naltrexone is safe for their liver, it helps to reframe the question around what the real comparison is. The liver damage accumulating from continued heavy drinking, measured over months and years, vastly exceeds any theoretical signal from therapeutic-dose naltrexone. A medication that helps someone drink less or stop entirely is, on balance, one of the most protective things that liver will encounter.

For a deeper look at how alcohol-related liver damage progresses and what symptoms appear at different stages, our article on signs of liver failure from alcohol covers the clinical picture in plain language.

Liver Monitoring: What to Expect When You Start Naltrexone

Responsible naltrexone prescribing includes baseline liver function testing and periodic monitoring. This is not because the drug is expected to cause liver damage at therapeutic doses. It is good clinical practice for any patient population that has been drinking heavily, and it provides reassurance for both patient and prescriber.

According to clinical guidelines published by NCBI's treatment protocol for oral naltrexone, a standard monitoring schedule involves liver function tests before starting the medication and again at one, three, and six months, then annually. Patients with pre-existing enzyme elevations or those taking higher doses may be tested more frequently.

If liver function tests rise significantly after starting naltrexone, beyond what would be expected from ongoing alcohol use, a prescriber will evaluate whether to adjust the dose or discontinue. In practice, this scenario is rare at the standard 50 mg dose. Most patients who are screened appropriately at baseline will not develop significant liver enzyme changes attributable to the medication.

Many patients actually find that their liver numbers improve over the course of treatment as their drinking decreases. That is exactly what the research would predict.

What the Large-Scale Research Actually Shows

The most rigorous modern evidence on naltrexone safety comes from a 2023 meta-analysis published in JAMA that analyzed 118 clinical trials involving 20,976 participants. The study identified oral naltrexone at 50 mg as one of the two strongest first-line pharmacotherapies for alcohol use disorder.

The primary adverse effect associated with naltrexone in this analysis was nausea, with a risk ratio of 1.73 compared to placebo. There was no significant hepatotoxicity signal across this pool of trials. The absence of a liver safety concern across nearly 21,000 patients is meaningful. If naltrexone at therapeutic doses were routinely harming livers, it would show up in a data set of that size.

The clinical picture is consistent: naltrexone 50 mg is well-tolerated by most patients, its main side effects are gastrointestinal and tend to diminish over the first few weeks, and its liver safety profile at therapeutic doses does not support the level of prescriber hesitancy that has historically surrounded it.

Why Prescriber Hesitancy Still Persists

It is worth addressing why the liver-safety conversation around naltrexone has stayed so charged even as the evidence has become clearer.

Part of it is the black-box warning's legacy. Even though the FDA removed it in 2013, the memory of it shapes clinical training and prescribing culture. Physicians who trained when the warning was active carry that association, and it takes time for institutional norms to catch up with regulatory updates.

Part of it is also the nature of prescribing in addiction medicine generally. Alcohol use disorder has historically been treated as a behavioral or willpower problem rather than a medical one. That framing has made clinicians slower to adopt pharmacological tools and quicker to elevate any safety concern when they do consider them.

The result is a treatment gap that costs patients real outcomes. Naltrexone is FDA-approved, backed by 30 years of data and more than 100 clinical trials, proven to reduce drinking frequency and the intensity of cravings, and safe for most people at the standard dose. Yet only a small fraction of the people who could benefit are ever offered it.

The Bottom Line on Naltrexone and Your Liver

Here is a plain-language summary of where the evidence stands:

• Naltrexone at the standard 50 mg therapeutic dose does not cause clinically meaningful liver damage in patients without pre-existing severe hepatic disease.

• The hepatotoxicity data that led to the original black-box warning came from doses of 300 mg per day, six times the therapeutic dose for alcohol use disorder.

• The FDA removed the black-box liver warning in 2013 after reviewing the accumulated evidence.

• Naltrexone is contraindicated in acute hepatitis and severe hepatic failure, but not in patients with modestly elevated liver enzymes from alcohol use.

• Liver monitoring is still recommended and is good clinical practice, not a sign that the drug is expected to cause damage.

• Continued heavy drinking causes far more liver damage than naltrexone does. A medication that helps someone drink less is, in most cases, a net positive for liver health.

If you have been hesitant about naltrexone specifically because of liver concerns, the evidence suggests those concerns were rooted in a clinical picture that no longer reflects how the drug is prescribed or what the research shows.

Taking a Step Forward

Getting accurate information is the first step. The next is finding out whether naltrexone is the right fit for where you are right now.

Choose Your Horizon offers an online Alcohol Use Assessment that connects you with a licensed physician who can review your health history, including any liver-related concerns, and determine whether naltrexone makes sense for you. The process is fully online, discreet, and typically completed within hours. If you are approved, medication ships to your door in 2 to 3 days.

You do not need to have hit rock bottom. You just need to want things to be different.

Take the online Alcohol Use Assessment and see if naltrexone could be a good fit for you.